Conferences


Digital Proteomics at ASMS 2017
14 Jun 2017

Digital Proteomics at ASMS 2017

We just wrapped up another amazing ASMS in Indianapolis! If you missed us last week, we’ve uploaded the literature from our booth to the Literature page.  There you will find our poster on untargeted metabolomics analysis, including case studies for pharmacokinetics and metabolomics identification using Quorum.  You’ll also see a new case study on sequencing an unusual antibody sample containing one heavy chain and two...

Read More


Digital Proteomics at Peptalk 2017
13 Jan 2017

Digital Proteomics at Peptalk 2017

Natalie presented the latest development to Valens and Alicanto at Peptalk 2017.  Alicanto is our multi-omic approach to antibody discovery that integrates B-cell transcript sequencing with mass spectrometry-based analysis of serum antibodies.  The sequenced repertoire containing tens or hundreds of thousands of sequences is screened using the mass spectra to identify circulating antibodies.  Optimized proteomics protocol achieves high antibody coverage of the variable domain and distinguishes with high...

Read More


A visit to the Lone Star State
13 Jun 2016

A visit to the Lone Star State

We met so many interesting people at ASMS 2016 in San Antonio.  Digital Proteomics made a big splash with our revamped Molecular Networks and Enosi software.  Our antibody sequencing service, Valens, continues to lead its class in accuracy, as well.  If you missed us, we have put up our latest posters and papers on our lit page.  We sampled our share of tex mex and it...

Read More


Digital Proteomics at MSACL 2016
07 Apr 2016

Digital Proteomics at MSACL 2016

We presented a workflow for drug discovery from environmental samples using Molecular Networks.  Molecular networks are a powerful tool for visualizing similarities in molecules including peptides and metabolites.  Using our tool for constructing Molecular Networks, we compared spectra from environmental samples from Panama and the Red Sea to a library of 535 FDA approved natural products.  Check out the findings in our poster.  Palm Springs, CA in March...

Read More


A better antibody with LakePharma
07 Oct 2015

A better antibody with LakePharma

Digital Proteomics collaborated with LakePharma, Inc. to create a better antibody targeting FLAG-tag.  We presented our results at the Protein Engineering Symposium in San Francisco.  Using Valens, we were able to determine the primary sequence of the Anti-FLAG® M2 antibody.  The recombinant antibody with a human constant region was transfected into CHO cells.  The new antibody showed 10 times greater binding capacity to the original antibody....

Read More


Soil metaproteomics with ENOSI
03 Jun 2015

Soil metaproteomics with ENOSI

At ASMS 2015, we presented groundbreaking work in metaproteomics using our proteogenomic toolkit, ENOSI. Despite the lack of an accurate reference gnome for many of the species suspected in the proteomic sample, ENOSI was able to use RNA-seq data to identify variation in homologous genomes. Using only publicly available proteomic, transcriptomic, and genomic data, we were able to identify interesting peptides. Read the details on...

Read More


Resurrecting monoclonal antibodies with VALENS
31 Mar 2015

Resurrecting monoclonal antibodies with VALENS

We presented the methodology behind our monoclonal antibody sequencing service, Valens at MSACL in San Diego. Armed with only the antibody protein and no genomic or transcriptomic information, Valens can recover the complete sequence of both the heavy and light chains. In addition, we can identify sites of liability, including those sites susceptible to oxidation and deamidation. Read the details on our poster


From monoclonal to polyclonal antibodies with VALENS
19 Jan 2015

From monoclonal to polyclonal antibodies with VALENS

Valens is a powerful tool for de novo sequencing of monoclonal antibodies. At PepTalk 2015, we explored the capability of Valens to sequence mixtures of monoclonal antibodies, which are of great relevance in the development of therapeutics. From a simulated mixture of 3 monoclonal antibodies, Valens was able to recover 88% of the sequence of the most abundant form. We are excited by the prospect...

Read More